Triptans stop migraines by activating specific serotonin receptors in the brain, which triggers a chain of effects: narrowing dilated blood vessels around the brain, reducing the release of inflammatory pain signals from nerve endings, and blocking pain transmission in the trigeminal nerve system. Standard doses relieve headache within two hours in 42 to 76% of patients, depending on the specific triptan used.
The Three Ways Triptans Fight a Migraine
Triptans lock onto two specific serotonin receptors, called 5-HT1B and 5-HT1D. These receptors sit on blood vessels and nerve endings involved in migraine pain. When a triptan activates them, three things happen more or less simultaneously.
First, swollen blood vessels in the membranes surrounding the brain constrict. During a migraine, these vessels dilate and press on surrounding tissue, contributing to the pounding quality of the pain. Triptans reverse that dilation.
Second, triptans quiet the trigeminal nerve, which is the main pain highway connecting your face and head to your brain. During a migraine, trigeminal nerve endings release inflammatory molecules, most notably one called CGRP (calcitonin gene-related peptide). CGRP sensitizes surrounding tissue and amplifies pain signals. Triptans suppress the release of CGRP, and clinical studies confirm that successful triptan treatment brings CGRP levels back to normal. This is the same molecule that newer migraine drugs (CGRP antibodies) target directly.
Third, triptans block pain signals from being transmitted deeper into the central nervous system. Even if some pain signaling starts at the nerve endings, triptans can interrupt it before it reaches the brain regions where you actually perceive the headache.
Vasoconstriction Is Only Part of the Story
For decades, migraines were thought to be fundamentally a blood vessel problem: vessels dilate, head hurts. Early evidence supported this because vasoconstrictors like ergotamine reliably relieved migraine pain. Triptans were originally designed around this same idea.
More recent research has complicated that picture. A key study found no significant changes in blood vessel diameter during spontaneous migraines in humans, leading the researchers to conclude that vasodilation alone doesn’t cause migraine pain. The field has largely shifted toward viewing migraine as a neurological event in which blood vessels play a supporting role rather than the starring one.
This matters because it explains why triptans work through more than just squeezing blood vessels shut. The neuronal effects, blocking inflammatory molecule release and interrupting pain transmission, appear to be equally or more important. Vessels and nerves engage in a two-way conversation: neurons release substances like CGRP that act on blood vessels, and vascular cells release factors that sensitize neurons, creating a feedback loop that amplifies pain. Triptans interrupt this loop at multiple points.
How Different Triptans Compare
Seven triptans are available: sumatriptan (the original, marketed in the early 1990s), plus zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan, and frovatriptan. They all target the same receptors, but they differ in how quickly they work, how long they last, and how much of the pill actually reaches your bloodstream.
Sumatriptan has a half-life of roughly 2 hours and only 14% oral bioavailability, meaning most of the pill never makes it into your blood. The six newer triptans were designed to improve on these numbers. They generally have higher bioavailability, longer half-lives, and stronger receptor binding. Almotriptan, for example, has about 70% bioavailability with peak blood levels at 1 to 3 hours after taking it. At the other end of the spectrum, frovatriptan has the longest half-life of any triptan at roughly 25 to 26 hours, making it useful for migraines that tend to recur over a stretch of time, such as menstrual migraines.
In a large meta-analysis, 2-hour pain freedom (going from moderate or severe pain to no pain) ranged from 18 to 50% depending on the triptan. If you broaden the measure to any meaningful improvement in pain, that range climbs to 42 to 76%. If one triptan doesn’t work well for you, a different one might, because the pharmacological differences between them are real even if subtle.
Chest Tightness and Other Triptan Sensations
Some people experience a cluster of odd sensations shortly after taking a triptan: tightness or pressure in the chest, tingling in the limbs, a feeling of heaviness, or warmth in the throat. These are commonly called “triptan sensations,” and they alarm people who worry about heart-related side effects.
In clinical trials, chest symptoms showed up in 1 to 4% of patients at standard doses. But when researchers specifically asked patients about chest symptoms, up to 41% reported them. The gap suggests many of these sensations are mild enough to go unreported unless prompted. In most patients, these symptoms are unrelated to the heart. Pulmonary vasoconstriction (temporary narrowing of blood vessels in the lungs) is one proposed explanation, though the exact cause isn’t fully settled. The sensations are typically brief and resolve on their own.
Why Triptans Are Restricted for Heart Conditions
Because triptans constrict blood vessels, they carry a risk for people whose cardiovascular system is already compromised. The FDA contraindicates all triptans in patients with coronary artery disease, coronary artery vasospasm, peripheral artery disease, stroke history, uncontrolled high blood pressure, and ischemic bowel disease. Additional conditions that clinicians consider off-limits include life-threatening arrhythmias, structural heart disease, and the presence of cardiac implants like coronary grafts. The concern is straightforward: a drug that narrows blood vessels could reduce blood flow to areas that are already getting too little.
Triptans and Antidepressants
In 2006, the FDA issued an advisory warning that combining triptans with SSRI or SNRI antidepressants might cause serotonin syndrome, a potentially dangerous condition caused by too much serotonin activity in the brain. This worried a lot of people, since migraine and depression frequently overlap, and many patients were taking both drug classes.
A large study of nearly 48,000 triptan users, including over 19,000 who took triptans alongside antidepressants, found the actual risk to be extremely low. Over 30,000 person-years of combined exposure, only 2 patients developed definite serotonin syndrome. Even counting possible cases, the incidence was just 2.3 cases per 10,000 person-years. The biological reason for this low risk makes sense: serotonin syndrome is primarily driven by a different serotonin receptor (2A) than the ones triptans target (1B and 1D). Triptans have only low affinity for the receptor most implicated in the syndrome. The study’s authors concluded that the FDA advisory should be reconsidered, and prescribing patterns suggest most clinicians agree, as coprescription rates did not decline after the warning.